Trader consensus reflected in the 96.8% market-implied odds for “No” stems from the absence of any licensed hantavirus vaccine for New World strains such as Andes virus, with all candidates still confined to preclinical or early-phase studies as of September 2026. Official surveillance confirms no FDA-approved options exist, and recent mRNA and DNA candidates from Moderna-Korea University collaborations and USAMRIID have completed only mouse efficacy work or small Phase 1 safety trials requiring multiple doses, without Phase 3 efficacy data. The May 2026 cruise-ship cluster raised visibility but did not accelerate regulatory timelines or initiate large-scale human trials. A realistic shift would require an unforeseen major outbreak triggering emergency authorization pathways or rapid Phase 3 initiation, though the disease’s low incidence continues to complicate such development.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गयाHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
3% संभावना
$139,010 वॉल्यूम
$139,010 वॉल्यूम
31 दिस, 2026
3% संभावना
$139,010 वॉल्यूम
$139,010 वॉल्यूम
31 दिस, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus reflected in the 96.8% market-implied odds for “No” stems from the absence of any licensed hantavirus vaccine for New World strains such as Andes virus, with all candidates still confined to preclinical or early-phase studies as of September 2026. Official surveillance confirms no FDA-approved options exist, and recent mRNA and DNA candidates from Moderna-Korea University collaborations and USAMRIID have completed only mouse efficacy work or small Phase 1 safety trials requiring multiple doses, without Phase 3 efficacy data. The May 2026 cruise-ship cluster raised visibility but did not accelerate regulatory timelines or initiate large-scale human trials. A realistic shift would require an unforeseen major outbreak triggering emergency authorization pathways or rapid Phase 3 initiation, though the disease’s low incidence continues to complicate such development.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
बाज़ार खुला: May 4, 2026, 10:39 AM ET
वॉल्यूम
$139,010समाप्ति तिथि
1 जन, 2027बाज़ार खुला
May 4, 2026, 10:39 AM ETरिज़ॉल्वर
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus reflected in the 96.8% market-implied odds for “No” stems from the absence of any licensed hantavirus vaccine for New World strains such as Andes virus, with all candidates still confined to preclinical or early-phase studies as of September 2026. Official surveillance confirms no FDA-approved options exist, and recent mRNA and DNA candidates from Moderna-Korea University collaborations and USAMRIID have completed only mouse efficacy work or small Phase 1 safety trials requiring multiple doses, without Phase 3 efficacy data. The May 2026 cruise-ship cluster raised visibility but did not accelerate regulatory timelines or initiate large-scale human trials. A realistic shift would require an unforeseen major outbreak triggering emergency authorization pathways or rapid Phase 3 initiation, though the disease’s low incidence continues to complicate such development.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
वॉल्यूम
$139,010समाप्ति तिथि
1 जन, 2027बाज़ार खुला
May 4, 2026, 10:39 AM ETरिज़ॉल्वर
0x65070BE91...Trader consensus reflected in the 96.8% market-implied odds for “No” stems from the absence of any licensed hantavirus vaccine for New World strains such as Andes virus, with all candidates still confined to preclinical or early-phase studies as of September 2026. Official surveillance confirms no FDA-approved options exist, and recent mRNA and DNA candidates from Moderna-Korea University collaborations and USAMRIID have completed only mouse efficacy work or small Phase 1 safety trials requiring multiple doses, without Phase 3 efficacy data. The May 2026 cruise-ship cluster raised visibility but did not accelerate regulatory timelines or initiate large-scale human trials. A realistic shift would require an unforeseen major outbreak triggering emergency authorization pathways or rapid Phase 3 initiation, though the disease’s low incidence continues to complicate such development.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया
बाहरी लिंक से सावधान रहें।
बाहरी लिंक से सावधान रहें।
अक्सर पूछे जाने वाले प्रश्न